The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It's a long time ago but did you know...'Eliot Forster served as Head of Development and Operations for the European Union and Asia at Pfizer Inc. from 1996 to 2007'...
Why did Levicept hire Eliot Foster as their CEO? And who would have made the decision? As I said...you need to look at who was on the Board at the time. Networking, networking, networking...fills board seats of established companies not ads and head hunters...ads and head hunters are used just to meet employment regs.
You are all assuming he was pushed...well maybe as a scientist he just wants to stay close to the lab. Once a compsny goes into commercialisation mode the CEOs job takes on a different focus. Plus the DX side has grown by a huge number of new personnel etc. Maybe he just feels more comfortable with testubes rather than people politics. Maybe he just loves being head of a start up rather than a global to be.
Think it's time to just put it all to bed now...he's gone...he did his job to the best of his ability and now he's moved on...the end.
Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. We identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.'
They are invested in Levicepts and Eliot is their CEO...
Https://www.pfizer.com/und/science/clinical-trials/integrity-and-transparency/stem-cell-research
Coincidence or what.
Avacta signposts European specialist fund invested and now our psrtners on FE are signposting they are in discussions with EU based company builder...
Would be amazing if they were the same company...just got to wait and see...
'Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.'
Note wording...
Anticipates...
Review not complete review...
We are only 10 May at the end of a holiday week...my guess is we will get info next week due to many people at Avacta being on holiday this week...simples...
I assume the SDMC is independent and therefore Avacta have to wait on them/wait their turn.
'A data monitoring committee (DMC) is a group of clinicians and biostatisticians appointed by study sponsors who provide independent assessment of the safety, scientific validity and integrity of clinical trials. In the United States, the Food and Drug Administration requires the formation of DMC in all trials that assess new interventions.'
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118004/
Part 2
Eliot Forster has been CEO of Levicepts since November 2023 and replaced the founder/CEO.
October 2022 - First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients.
September 2021 - Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.
March 2021 - Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept.
P1 data is key and we have been told Avactas P1 data so far has unlocked the pipeline...this is the start guys...and Avacta is now doing what so many do...and as said before if the likes of EF and CC can't bring on those deals or bring serious investors on board then we all need to pack our backs and move on...
This week is a rubbish week for news due to holidays...we are only 4 weeks away from June and My guess is that's when we will see things really start to kick off...however, there are the unanswered questions from the last Investor Meet regarding the Placing, the Placing Price, the European Fund...and I thnk we will get to know more before May is out...
OK so I've banged on about EF...but this might help you see why...these are his current positions and so company highlights which might indicate what sort of deals or investors we might hope to see.
Eliot Forster has been NE Director for Immatics NV (NASDAQ) since 2021and the following is from their March 2024 Y/E Results
First clinical data updates for Immatics’ next-generation TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity
In May 2023, Bristol Myers Squibb exercised first opt-in into the autologous cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment in July 2023
In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million upfront payment, and the total deal volume could exceed $1.7 billion
$201.5 million public offering completed on January 22, 2024
Eliot Forster has been Chairperson for Ochre Bio since May 2023
22 April 2024 — Ochre Bio today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases. In this multi-year, multi-target collaboration, Ochre Bio will receive up to USD 35 million in upfront and near-term research-based milestone payments. Ochre may also receive milestones for clinical, regulatory, and commercial success as well as tiered royalties with an overall deal value with the potential to exceed USD 1 billion.
Eliot Forster has been Chairman of Protalix Therapeutics since Sept 2023
On May 10, 2023, the Company announced that the U.S. Food and Drug Administration (FDA) approved Elfabrio in the United States for the treatment of adult patients with Fabry disease.
The FDA approval triggered a $20.0 million milestone payment from Chiesi. In addition, the Company generated $17.5 million from sales of Elfabrio to Chiesi during 2023 post-regulatory approval, as Chiesi is building its inventory and recruiting commercial patients in the United States and Europe.
Eliot Forster is also Chair of the Board of Tessellate Bio
Tessellate Bio was founded to develop precision oncology approaches to treat cancers with high unmet need. And their main investor is BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors. Strategic investors include Eli Lilly and Company, Novo Holdings and Bristol Myers Squibb. BGV co-founder and lead investor in Acerta which was sold to Astra Zenica in 2016 for up to $7 billion.
Cont...
If you wabt to understand where Avacta is heading follow the past history/actions/contacts of those in charge...in my experience they will continue to do what they've done in the past...history will repeat itself...
Too many outside factors for Avacta to keep to schedule...
Maybe they've had several more good recruits turn up do they got data review and safety clearance now dosing can be done in parallel and info will be given to when CC can give us more info like FDA approval.
CC is American and will be doong things very much her way which willbe very different to AS I suspect...she will be going for RNS's with impact.
One other scenario is they have a deal in the makjng and it's all quiet on all fronts for the moment...
Eliot has connections with this company too...
https://biogenerationventures.com/en/
Oh and BTW the founder of Levicept was made CSO when Eliot took over his CEO position.
Below is what happened at Levicept after their fundraise... founder dumped in favour of Eliot Forster...did the European fund have anything to do with AS being dumped. If Eliot bought the European fund to the table and they dictated price with much more funding to follow based on trial results, CEO upgrade, a place on the Board.
December 2023
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator, LEVI-04
November 2023
Levicept Appoints Eliot Forster as CEO
October 2022
First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients. Multiple arm, multi-centre, placebo-controlled study to evaluate five monthly infusions of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. ClinicalTrials.gov ID: NCT05618782
April 2022
Case Study interview with Simon Westbrook, CEO of Levicept in Bioprocess Online discussing his experience in selecting and working with a global CDMO partner, and the value Lonza brought to his virtual company.
https://www.bioprocessonline.com/doc/illustrating-a-successful-small-biotech-cdmo-relationship-0002
September 2021
Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.
March 2021
Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept. ClinicalTrials.gov ID: NCT03227796